'Lack of trust' in medicines prompts UK review
This article was originally published in SRA
The pharmaceutical industry in the UK will be invited to have its say in a project that will explore concerns by England's chief medical officer that high-profile media debates over certain drugs have damaged trust in clinical researchers, drug companies and doctors1.
You may also be interested in...
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated to include a new product – Alnylam Pharmaceuticals' Givlaari for treating acute hepatic porphyria. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
The health technology assessment institute is taking a virtual approach to meetings and has said that it can provide free fast-track advice for companies developing novel diagnostics or therapeutics for the coronavirus.
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.